INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus.
Phase of Trial: Phase IV
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Temsirolimus (Primary)
- Indications Mantle-cell lymphoma; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms INHIBITOR
- Sponsors Pfizer
- 07 May 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 01 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 01 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.